Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.
Clin Infect Dis. 2013 Dec;57 Suppl 3(Suppl 3):S139-70. doi: 10.1093/cid/cit578.
In this IDSA policy paper, we review the current diagnostic landscape, including unmet needs and emerging technologies, and assess the challenges to the development and clinical integration of improved tests. To fulfill the promise of emerging diagnostics, IDSA presents recommendations that address a host of identified barriers. Achieving these goals will require the engagement and coordination of a number of stakeholders, including Congress, funding and regulatory bodies, public health agencies, the diagnostics industry, healthcare systems, professional societies, and individual clinicians.
在这份 IDSA 政策文件中，我们回顾了当前的诊断领域，包括未满足的需求和新兴技术，并评估了改进检测方法的开发和临床应用所面临的挑战。为了实现新兴诊断技术的潜力，IDSA 提出了一系列建议，以解决已确定的诸多障碍。要实现这些目标，需要包括国会、资金和监管机构、公共卫生机构、诊断行业、医疗保健系统、专业协会和临床医生在内的多个利益相关者的参与和协调。
